Literature DB >> 29502901

The Mexican consensus on the diagnosis and treatment of ulcerative colitis.

J K Yamamoto-Furusho1, Y Gutiérrez-Grobe2, J G López-Gómez3, F Bosques-Padilla4, J L Rocha-Ramírez5.   

Abstract

The guidelines presented herein are an updated version of the recommendations published in 2007. Since then, there has been a rapid advance in the knowledge about the pathophysiology of ulcerative colitis and its therapeutic options. New drugs have been approved, novel targeted therapies have emerged, and new strategies have been developed to improve the previously available approaches to the disease. The aim of the present consensus is to promote the current knowledge of and Mexican perspective on the epidemiology, diagnosis, and medical and surgical treatment of chronic idiopathic ulcerative colitis. The final vote on the statements and their ultimate modifications were carried out at the consensus working group meeting. Evidence was evaluated through the GRADE classification.
Copyright © 2018 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A. All rights reserved.

Entities:  

Keywords:  Colectomy; Colectomía; Colitis ulcerosa crónica idiopática; Diagnosis; Diagnóstico; Epidemiology; Epidemiología; Pouchitis; Tratamiento; Treatment; Ulcerative colitis

Mesh:

Substances:

Year:  2018        PMID: 29502901     DOI: 10.1016/j.rgmx.2017.08.006

Source DB:  PubMed          Journal:  Rev Gastroenterol Mex (Engl Ed)        ISSN: 2255-534X


  7 in total

1.  Correlation of ulcerative colitis and colorectal cancer: a systematic review and meta-analysis.

Authors:  Yansong Wang; Pu Wang; Lixiang Shao
Journal:  J Gastrointest Oncol       Date:  2021-12

2.  The combined efficacy of adalimumab with GMA method on the treatment of ulcerative colitis and repair of intestinal mucosal lesion.

Authors:  Ailing Song; Hai Jiang; Liang Guo; Shanshan Wu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

3.  Network pharmacology for systematic understanding of Schisandrin B reduces the epithelial cells injury of colitis through regulating pyroptosis by AMPK/Nrf2/NLRP3 inflammasome.

Authors:  Weiwei Zhang; Wusan Wang; Chaozhuang Shen; Xiaohu Wang; Zhichen Pu; Qin Yin
Journal:  Aging (Albany NY)       Date:  2021-10-09       Impact factor: 5.682

4.  Effects of miR-939 and miR-376A on ulcerative colitis using a decoy strategy to inhibit NF-κB and NFAT expression.

Authors:  Yongwei Lin; Zhipeng Zhou; Lang Xie; Yongsheng Huang; Zhenghua Qiu; Lili Ye; Chunhui Cui
Journal:  Eur J Histochem       Date:  2022-02-15       Impact factor: 3.188

5.  Role of TRIM22 in ulcerative colitis and its underlying mechanisms.

Authors:  Bin Ye; Zhongkai Lu
Journal:  Mol Med Rep       Date:  2022-06-08       Impact factor: 3.423

6.  Patient knowledge of fecal calprotectin in inflammatory bowel disease (IBD): An observational study in Mexico.

Authors:  Brenda Maldonado-Arriaga; Sergio Sandoval-Jiménez; Juan Rodríguez-Silverio; Sofía Lizeth Alcaráz-Estrada; Tomás Cortés-Espinosa; Rebeca Pérez-Cabeza de Vaca; Jonathan Shaw; Paul Mondragón-Terán; Cecilia Hernández-Cortez; Juan Antonio Suárez-Cuenca; Graciela Castro-Escarpulli
Journal:  F1000Res       Date:  2020-12-21

7.  Anti-Inflammatory and Antioxidant Activities of the Methanolic Extract of Cyrtocarpa procera Bark Reduces the Severity of Ulcerative Colitis in a Chemically Induced Colitis Model.

Authors:  Mario Rodriguez-Canales; Elizdath Martinez-Galero; Alma D Nava-Torres; Luvia E Sanchez-Torres; Leticia Garduño-Siciliano; Maria Margarita Canales-Martinez; Luis I Terrazas; Marco A Rodriguez-Monroy
Journal:  Mediators Inflamm       Date:  2020-04-21       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.